Search results | option

Reports

Option and Evaluation Agreements in Pharma and Biotech

The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.

Hearing Disorders Partnering

Hearing Disorders Partnering report provides understanding and access to the Hearing disorders partnering deals and agreements entered into by the worlds leading healthcare companies.

Idiopathic Pulmonary Fibrosis Partnering

The Idiopathic Pulmonary Fibrosis Partnering report provides understanding and access to the idiopathic pulmonary fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Smoking Cessation Partnering

Smoking Cessation Partnering report provides understanding and access to the smoking partnering deals and agreements entered into by the worlds leading healthcare companies.

Preventative Medicine Partnering

Preventative Medicine Partnering report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

Drug Addiction Partnering

Drug Addiction Partnering report provides understanding and access to the drug addiction partnering deals and agreements entered into by the worlds leading healthcare companies.

Obesity Partnering

Obesity Partnering report provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies.

Retinopathy Partnering

Retinopathy Partnering report provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies.

Dry Eye Partnering

Dry Eye Partnering report provides understanding and access to the dry eye partnering deals and agreements entered into by the worlds leading healthcare companies.

Conjunctivitis Partnering

Conjunctivitis Partnering report provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Packaging your offering – Option and evaluation agreements

CP Insight > Insight Toolkit > Finding Partners > Packaging your offering – Option and evaluation agreements At a certain stage after initial evaluation of partnering opportunities, the potential licensee company may seek to exclude competitors from evaluating the opportunity for a set period of time, or enter into an option agreement that provides the licensee company with first refusal on a more »

Option

The term option within an deal refers to an integral part of an agreement already entered by the parties…

Option and evaluation: recent partnering industry trends

The article here analyses the recent partnering industry trends in the option and evaluation deal type areas. There are two major forms of deal terms that allow a party to secure rights to an asset subject to a future event

Elan receives $6.7 billion M&A offer from Royalty Pharma with options to the overall sum of $8 billion

Royalty Pharma has raised its bid for Elan again. With sum m&a value now sitting at $6.7 billion with options bringing the overall deal value to $8 billion.

Pharma news: Roche explores expansion options after Illumina fends its hostile bid

The top pharma news hitting the headlines is, Roche’s desire to still expand in gene sequencing after its failed attempt to buy Illumina Inc. (ILMN) this year

M&A trends: Warner Chilcott Said to Consider Options After Interest

Warner Chilcott is weighing options including a possible M&A after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter. The shares jumped in early trading

Roche has other options if Illumina hostile takeover fails, Humer says

Roche Holding AG, the Swiss drugmaker that made a $5.7 billion hostile offer for the gene- mapping company Illumina Inc. (ILMN), said it has other options if the deal falls through. 

Alexza to explore strategic options

Written by Soham Chatterjee for Reuters. Alexza Pharmaceuticals Inc said it will explore options including sale of assets, strategic business combination, or partnerships. 

Janssen secures options to DARPins in deal worth up to $800 million

Janssen Biotech, a subsidiary of Johnson & Johnson, has secured a long term collaborative R&D deal with Molecular Partners for the development of novel multispecific DARPin products for up to four unmet need immunological disease targets

Option-based deals: How biotechs and big pharmas share R&D risk

Published by MedCity News. 

Events

Leidos signs a pharma deal with US Defense Department

Leidos was awarded a pharma deal with prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction.

Deals

Pfizer in asset purchase and option to acquire AM-Pharma

Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

BMS signs an optional pharma deal with Galecto worth $444 million

Bristol-Myers Squibb signed a pharma deal for an exclusive option to acquire Galecto Biotech and gain worldwide rights to its lead asset TD139.

Global Green, Inc. Signs Agreement with Merial for Evaluation of Salmonella Vaccine and License Option

Global Green announces the signing of an agreement with Merial to conduct an internal evaluation of Global Green’s patented Salmogenics vaccine technology.

Teva does not use option from Rexahn pharma deals

Rexahn Pharmaceuticals announced that Teva Pharmaceutical Industries has decided, for strategic reasons, not to exercise its option to license RX-3117 from Rexahn from previous pharma deals.

Celgene pharma partners with option to buy Acetylon

Acetylon Pharmaceuticals pharma partners as part of a strategic collaboration and option agreement with Celgene , which aids the development of Acetylon’s various portfolios

Boehringer Ingelheim big pharma deals Athera Biotech for novel cardiovascular antibody option agreement

Athera Biotechnologies has entered into pharma deals involving an option agreement with Boehringer Ingelheim on a novel preclinical antibody program.

Grifols big pharma deals Aradigm in licensing and option agreement for Pulmaquin, Lipoquin and AERx

Grifols, a big pharma company, has entered pharma deals with Aradigm for licensing and options relating to Pulmaquin, Lipoquin and AERx.

Celgene co-promotion, collaborative R&D and option agreement with FORMA for protein homeostasis targets regulation drug

FORMA Therapeutics announced a strategic collaboration, co-promotion and option agreement with Celgene Corporation under which FORMA and Celgene will discover, develop and commercialize drug candidates to regulate protein homeostasis targets.

Merck in pharma licensing and option deal with Xenon

Big pharma company, Merck, in pharma licensing deal with Xenon stemming from a previous option agreement.

Pharma news: Roche explores expansion options after Illumina fends its hostile bid

The top pharma news hitting the headlines is, Roche’s desire to still expand in gene sequencing after its failed attempt to buy Illumina Inc. (ILMN) this year